American Journal of Neuroradiology, Vol 18, Issue 7 1271-1277, Copyright © 1997 by American Society of Neuroradiology
ARTICLES |
Neurometabolism of active neuropsychiatric lupus determined with proton MR spectroscopy
WL Sibbitt Jr, LJ Haseler, RR Griffey, SD Friedman and WM Brooks
Center for Non-Invasive Diagnosis, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque 87131, USA.
PURPOSE: To determine the neurometabolism of patients with active neuropsychiatric systemic lupus erythematosus (NPSLE) by using proton MR spectroscopy. METHODS: Thirty-six patients with SLE and eight control subjects were studied with proton MR spectroscopy to measure brain metabolites. Peaks from N-acetylaspartate (NAA), creatine (Cr), choline (Cho), and at 1.3 parts per million (ppm) lipid, macromolecules, and lactate were measured. Patients were classified as having major NPSLE (seizures, psychosis, major cognitive dysfunction, delirium, stroke, or coma) (n = 15) or minor NPSLE (headache, minor affective disorder, or minor cognitive disorder) (n = 21). Patients with major NPSLE were severely ill and hospitalized. RESULTS: SLE patients had lower NAA and increased metabolites at 1.3 ppm than did control subjects (NAA/Cr(SLE) = 1.90 +/- 0.35, NAA/Cr(Control) = 2.16 +/- 0.26; 1.3 ppm/Cr(SLE) = 0.49 +/- 0.41, 1.3 ppm/Cr(Control) = 0.27 +/- 0.05). NAA/Cr in patients with current or prior major NPSLE was lower than in patients without major NPSLE. Increased peaks at 1.3 ppm were present in all SLE subgroups, but particularly in patients with major NPSLE. These resonances were not evident at an echo time of 136, indicating that these signals were not lactate. CONCLUSION: Major NPSLE, past or present, is associated with decreased levels of NAA. Elevated peaks around 1.3 ppm do not represent lactate even in severely ill patients, indicating that global ischemia is not characteristic of NPSLE. Neurochemical markers determined by MR spectroscopy may be useful for determining activity and degree of brain injury in NPSLE.
This article has been cited by other articles:
 |
|
 |
|
  M. Petrou, R.E. Harris, B.R. Foerster, S.A. Mclean, A. Sen, D.J. Clauw, and P.C. Sundgren Proton MR Spectroscopy in the Evaluation of Cerebral Metabolism in Patients with Fibromyalgia: Comparison with Healthy Controls and Correlation with Symptom Severity AJNR Am. J. Neuroradiol., May 1, 2008; 29(5): 913 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Appenzeller, L.M. Li, L.T.L. Costallat, and F. Cendes Neurometabolic changes in normal white matter may predict appearance of hyperintense lesions in systemic lupus erythematosus Lupus, December 1, 2007; 16(12): 963 - 971. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Appenzeller, L. M. Li, L. T. L. Costallat, and F. Cendes Evidence of reversible axonal dysfunction in systemic lupus erythematosus: a proton MRS study Brain, December 1, 2005; 128(12): 2933 - 2940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C.A. Steens, G. M. Steup-Beekman, G. P.Th. Bosma, F. Admiraal-Behloul, H. Olofsen, J. Doornbos, T. W.J. Huizinga, and M. A. van Buchem The Effect of Corticosteroid Medication on Quantitative MR Parameters of the Brain AJNR Am. J. Neuroradiol., November 1, 2005; 26(10): 2475 - 2480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Castellino, M Govoni, M Padovan, P Colamussi, M Borrelli, and F Trotta Proton magnetic resonance spectroscopy may predict future brain lesions in SLE patients: a functional multi-imaging approach and follow up Ann Rheum Dis, July 1, 2005; 64(7): 1022 - 1027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Mitsikostas, P. P. Sfikakis, and P. J. Goadsby A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth Brain, May 1, 2004; 127(5): 1200 - 1209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Govoni, G Castellino, M Padovan, M Borrelli, and F Trotta Recent advances and future perspective in neuroimaging in neuropsychiatric systemic lupus erythematosus Lupus, March 1, 2004; 13(3): 149 - 158. [Abstract] [PDF]
|
|
|
|
|
|
P L Peterson, F A Howe, C A Clark, and J S Axford Quantitative magnetic resonance imaging in neuropsychiatric systemic lupus erythematosus Lupus, December 1, 2003; 12(12): 897 - 902. [Abstract] [PDF]
|
|
|
|
|
|
S C A Steens, G P T. Bosma, R ten Cate, J Doornbos, J M Kros, L A E M Laan, G M Steup-Beekman, M A van Buchem, and T W J Huizinga A neuroimaging follow up study of a patient with juvenile central nervous system systemic lupus erythematosus Ann Rheum Dis, June 1, 2003; 62(6): 583 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. V. C. Portela, J. C. T. Brenol, R. Walz, M. Bianchin, A. B. L. Tort, U. P. Canabarro, S. Beheregaray, J. A. Marasca, R. M. Xavier, E. C. Neto, et al. Serum S100B Levels in Patients with Lupus Erythematosus: Preliminary Observation Clin. Vaccine Immunol., January 1, 2002; 9(1): 164 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J S Axford, F A Howe, C Heron, and J R Griffiths Sensitivity of quantitative 1H magnetic resonance spectroscopy of the brain in detecting early neuronal damage in systemic lupus erythematosus Ann Rheum Dis, February 1, 2001; 60(2): 106 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kadota, T. Horinouchi, and C. Kuroda Development and Aging of the Cerebrum: Assessment with Proton MR Spectroscopy AJNR Am. J. Neuroradiol., January 1, 2001; 22(1): 128 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Lim, C. H. Suh, H. J. Kim, Y. K. Cho, S. H. Choi, J. H. Kang, W. Park, and J. H. Lee Systemic Lupus Erythematosus: Brain MR Imaging and Single-Voxel Hydrogen 1 MR Spectroscopy Radiology, October 1, 2000; 217(1): 43 - 49. [Abstract] [Full Text]
|
|
|
|
 |
|
 M Rovaris, B Viti, G Ciboddo, S Gerevini, R Capra, G Iannucci, G Comi, and M Filippi Brain involvement in systemic immune mediated diseases: magnetic resonance and magnetisation transfer imaging study J. Neurol. Neurosurg. Psychiatry, February 1, 2000; 68(2): 170 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sabet, W. L. Sibbitt Jr, C. A. Stidley, J. Danska, and W. M. Brooks Neurometabolite Markers of Cerebral Injury in the Antiphospholipid Antibody Syndrome of Systemic Lupus Erythematosus Stroke, November 1, 1998; 29(11): 2254 - 2260. [Abstract] [Full Text] [PDF]
|
|